<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9866">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05688514</url>
  </required_header>
  <id_info>
    <org_study_id>INVL20-01-IL</org_study_id>
    <nct_id>NCT05688514</nct_id>
  </id_info>
  <brief_title>TVMR With the Innovalve System Trial - First In Human Israel</brief_title>
  <acronym>TWIST-FIHIL</acronym>
  <official_title>TVMR With the Innovalve System Trial - First In Human Israel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovalve Bio Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovalve Bio Medical Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the safety and performance of the Innovalve mitral valve replacement system&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multi-center, First-In-Human, prospective, single arm early feasibility study&#xD;
      to evaluate the safety and performance of the Innovalve mitral valve replacement system&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of implant or delivery related serious adverse events at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Absence of implant or delivery related serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>Procedure</time_frame>
    <description>All of the below:&#xD;
i. Absence of procedural mortality; and ii. Successful access, delivery, and retrieval of the device delivery system; and iii. Successful deployment and correct positioning of the first intended device; and iv. Freedom from emergency surgery or reintervention related to the device or access procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>30 days</time_frame>
    <description>All of the following must be present:&#xD;
I. Deployment of the device&#xD;
II. Absence of major device or procedure related serious adverse events, including:&#xD;
Death&#xD;
Stroke&#xD;
Life-threatening bleeding (MVARC scale)&#xD;
Major vascular complications&#xD;
Major cardiac structural complications&#xD;
Stage 2 or 3 acute kidney injury (includes new dialysis)&#xD;
Myocardial infarction or coronary ischemia requiring PCI or CABG&#xD;
Severe hypotension, heart failure, or respiratory failure requiring intravenous pressors or invasive or mechanical heart failure treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular or biventricular assist devices, or prolonged intubation for 48 h.&#xD;
Any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class</measure>
    <time_frame>30 days, 6, 12 months and annually up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six-minute walk test</measure>
    <time_frame>30 days, 6, 12 months and annually up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life improvement (KCCQ-12) Kensas City Cardiomyopathy Questionnaire</measure>
    <time_frame>30 days, 6, 12 months and annually up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Mitral Regurgitation grade</measure>
    <time_frame>30 days, 6, 12 months and annually up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Mitral Valve Regurgitation (Degenerative or Functional)</condition>
  <arm_group>
    <arm_group_label>Innovalve TMVR System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MV replacement with Innovalve MR system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Innovalve MR system</intervention_name>
    <description>Innovalve MR system</description>
    <arm_group_label>Innovalve TMVR System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically significant, symptomatic mitral regurgitation&#xD;
&#xD;
          -  High risk for open-heart surgery&#xD;
&#xD;
          -  Meets anatomical criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unsuitable anatomy&#xD;
&#xD;
          -  Patient is inoperable&#xD;
&#xD;
          -  EF&lt;25%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Director Clinical Affairs</last_name>
    <phone>+972-3-5308058</phone>
    <email>clinicaltrials@innovalemed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miriam Ivenshitz, PhD</last_name>
    <phone>+972-53-9516947</phone>
    <email>miriam@innovalvemed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Guetta, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 22, 2022</study_first_submitted>
  <study_first_submitted_qc>January 15, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2023</study_first_posted>
  <last_update_submitted>January 15, 2023</last_update_submitted>
  <last_update_submitted_qc>January 15, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

